Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Orasure Technologies ( (OSUR) ) has issued an update.
OraSure Technologies announced its financial results for the third quarter of 2025, reporting $27.1 million in revenue. Despite challenges related to funding uncertainties for public health programs, the company is optimistic about returning to growth in 2026 through product diversification and new product launches. The company is focusing on decentralizing diagnostics to make healthcare more accessible and personalized, with upcoming products like the Sherlock over-the-counter molecular self-test for Chlamydia and Gonorrhoeae and the Colli-Pee urine self-collection for sexually transmitted infections.
The most recent analyst rating on (OSUR) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Orasure Technologies stock, see the OSUR Stock Forecast page.
Spark’s Take on OSUR Stock
According to Spark, TipRanks’ AI Analyst, OSUR is a Neutral.
Orasure Technologies faces significant financial and technical challenges, reflected in its low financial performance and bearish technical indicators. While the earnings call provided some positive highlights, the overall sentiment remains cautious due to revenue declines and profitability issues. The stock’s valuation suggests potential if financial performance improves, but current conditions warrant a conservative outlook.
To see Spark’s full report on OSUR stock, click here.
More about Orasure Technologies
OraSure Technologies, Inc. is a leader in point-of-need and home diagnostic tests and sample management solutions.
Average Trading Volume: 534,372
Technical Sentiment Signal: Strong Sell
Current Market Cap: $188M
For a thorough assessment of OSUR stock, go to TipRanks’ Stock Analysis page.